US Neurosurgical Holding (US Neurosurgical Holding) ROCE % : -167.58% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is US Neurosurgical Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. US Neurosurgical Holding's annualized ROCE % for the quarter that ended in Dec. 2023 was -167.58%.

US Neurosurgical Holding ROCE % Historical Data

The historical data trend for US Neurosurgical Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Neurosurgical Holding ROCE % Chart

US Neurosurgical Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.30

24.74

-16.12

-67.70

-74.64

US Neurosurgical Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-223.93	-37.05	-89.22	-78.94	-167.58

US Neurosurgical Holding ROCE % Calculation

US Neurosurgical Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.814	/	( ( (1.747 - 0.28)	+	(1.321 - 0.607) )	/ 2 )
	=	-0.814	/	( (1.467	+	0.714)	/ 2 )
	=	-0.814	/	1.0905
	=	-74.64 %

US Neurosurgical Holding's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-1.168	/	( ( (0.871 - 0.191)	+	(1.321 - 0.607) )	/ 2 )
	=	-1.168	/	( ( 0.68	+	0.714 )	/ 2 )
	=	-1.168	/	0.697
	=	-167.58 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

US Neurosurgical Holding (OTCPK:USNU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

US Neurosurgical Holding ROCE % Related Terms

Thank you for viewing the detailed overview of US Neurosurgical Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

US Neurosurgical Holding (US Neurosurgical Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US Neurosurgical Holding Inc (OTCPK:USNU) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2400 Research Boulevard, Suite 325, Rockville, MD, USA, 20850

Website

http://www.usneuro.com

US Neurosurgical Holding Inc operates as a holding company in United State. It is a medical services company that partners with hospitals and physicians to operate facilities utilizing artistic and inventive technologies in medical treatment and diagnosis. It is engaged in providing medical treatment and diagnosis services that include stereotactic radiosurgery centers, utilizing gamma knife technology, and holds interests in radiological treatment facilities. The company is focusing on establishing cancer centers using intensity-modulated radiation therapy. Its gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery.

Executives

Lawrence William St	director	23 ASHLAND STREET, NEWBURYPORT MA 01950-1905
William F. Leimkuhler	director	43 SALEM STRAITS RD, DARIEN CT 06820
Merriman Charles H Iii	director
Alan Gold	director, 10 percent owner, officer: President & Chairman	2400 RESEARCH BLVD, SUITE 325, ROCKVILLE MD 20850
Stanley S Shuman	10 percent owner	C/O RIPPLEWOOD HOLDINGS LLC, ONE ROCKERFELLER PLAZA, NEW YORK NY 10020
Allen & Co Inc	10 percent owner	711 FIFTH AVENUE, NEW YORK NY 10022

US Neurosurgical Holding (US Neurosurgical Holding) Headlines

No Headlines